<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5705">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04564183</url>
  </required_header>
  <id_info>
    <org_study_id>20-1739</org_study_id>
    <nct_id>NCT04564183</nct_id>
  </id_info>
  <brief_title>Advancing Prevention of Pulmonary Fibrosis</brief_title>
  <acronym>APPLe</acronym>
  <official_title>Advancing Prevention of Pulmonary Fibrosis - A Cohort Study of Preclinical Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study plans to learn more about pulmonary fibrosis and how it develops. We want to&#xD;
      determine if the disease can be detected early, before the lung is permanently scarred.&#xD;
&#xD;
      This study will enroll participants who are not currently diagnosed with pulmonary fibrosis,&#xD;
      but who have family members with pulmonary fibrosis. BEcause there is an increased risk&#xD;
      within affected families, this cohort will allow us to learn how pulmonary fibrosis develops,&#xD;
      and how the lungs change over time.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Screen all subjects for early Idiopathic Pulmonary Fibrosis (IPF) with High Resolution CT Scan of the Chest</measure>
    <time_frame>Baseline</time_frame>
    <description>All subjects will be screened with a high resolution CT scan to identify early signs of lung fibrosis. CT scans will be evaluated by study radiologists.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>IPF</condition>
  <condition>Pulmonary Fibrosis</condition>
  <condition>ILD</condition>
  <arm_group>
    <arm_group_label>Full Cohort</arm_group_label>
    <description>Entire study population</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sub-Cohort</arm_group_label>
    <description>Randomly selected sub-cohort from the larger group of all participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sample collection</intervention_name>
    <description>Blood, Urine, Nail, Hair, Saliva, optional Stool</description>
    <arm_group_label>Full Cohort</arm_group_label>
    <arm_group_label>Sub-Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>SF-36, Food Frequency, Pulmonary Fibrosis Study questionnaire, COVID questionnaire</description>
    <arm_group_label>Full Cohort</arm_group_label>
    <arm_group_label>Sub-Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>High resolution CT scan of the chest</intervention_name>
    <description>Upon enrollment, all patients will undergo single prone volumetric thoracic chest CT scan. This will be performed at full inspiration using a 64-slice CT scanner.</description>
    <arm_group_label>Full Cohort</arm_group_label>
    <arm_group_label>Sub-Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Pulmonary Function Test</intervention_name>
    <description>All recruited subjects will undergo a pre-bronchodilator spirometry test and a lung diffusion capacity test, both in accordance with ATS guidelines. Exercise capacity (maximum physical exertion) will be assessed by performing a 6-minute walk test, also according to ATS guidelines.</description>
    <arm_group_label>Full Cohort</arm_group_label>
    <arm_group_label>Sub-Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        We will enroll up to 1,000 participants who are in families with two or more reported cases&#xD;
        of pulmonary fibrosis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unaffected first degree relative from Familial Interstitial Pneumonia families (two or&#xD;
             more family members with IIP)&#xD;
&#xD;
          -  Age at least 40 years old and younger than 75 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with known (physician-diagnosed) pulmonary fibrosis prior to informed&#xD;
             consent&#xD;
&#xD;
          -  Other genetic diseases associated with interstitial lung disease&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Schwartz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel Warren</last_name>
    <phone>303-724-8569</phone>
    <email>rachel.warren@cuanschutz.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Avram Walts</last_name>
    <phone>303-724-6435</phone>
    <email>avram.walts@cuanschutz.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Warren, BA</last_name>
      <phone>303-724-8569</phone>
      <email>rachel.warren@cuanschutz.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 18, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

